文献速递浆细胞疾病

多发性骨髓瘤中的IMiD耐药:对基础生物学和临床影响的当前理解

IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact.
PubMed 文献 · Blood · 2023-01-01

免疫调节剂(IMiD)是多发性骨髓瘤治疗的基石,用于各阶段联合治疗及自体干细胞移植后单药维持,但患者最终耐药复发。近十年阐明IMiD通过结合CRL4CRBN E3泛素连接酶cereblon组分降解新底物(如Ikaros和Aiolos)导致IRF4和c-MYC降低及细胞死亡。本综述探讨IMiD耐药现有研究并提出未来研究方向。

要点

  • IMiD用于多发性骨髓瘤各阶段联合治疗及自体干细胞移植后单药维持。
  • IMiD结合CRL4CRBN E3泛素连接酶cereblon组分,降解Ikaros和Aiolos等新底物。
  • 骨髓瘤细胞中Ikaros和Aiolos降解导致IRF4和c-MYC水平降低及细胞死亡。

核心结论

  • 本综述探讨IMiD耐药现有研究并提出可能推进对该常见临床状况理解和管理的未来研究方向。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • IMiD通过结合CRL4CRBN E3泛素连接酶cereblon组分,指定一组新底物经蛋白酶体降解。
  • 骨髓瘤细胞中IMiD作用包括降解锌指B细胞转录因子Ikaros和Aiolos,导致IRF4和c-MYC水平降低及细胞死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory agents (IMiDs) are a cornerstone of treatment for patients with multiple myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are approved as a single-agent maintenance treatment after autologous stem cell transplantation. However, patients become resistant to ongoing therapy over time and inevitably relapse. It is only in the last decade that the mechanism of IMiD action has been elucidated; through binding to the cereblon component of the CRL4CRBN E3 ubiquitin ligase, a set of neosubstrates is designated for degradation by the proteasome. In myeloma cells, this includes the zinc-finger B-cell transcription factors Ikaros and Aiolos, which, in turn, lead to decreased levels of IRF4 and c-MYC and cell death. As our knowledge of IMiD mechanism of action has advanced, the ability to study resistance mechanisms has also developed. This review explores the existing work on IMiD resistance and proposes areas of future research that may advance our understanding and management of this common clinical condition.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood. 2023. PMID: 36929172. doi:10.1182/blood.2023019637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。